Drugs / Iparomlimab and Tuvonralimab
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 4 | NCT07854522 | Oct 2026 → Sep 2029 expected | melanoma | Peking University Cancer Hospital & Institute | Not yet recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2026-03-02 | Qilu Pharmaceutical Co., Ltd. | Results 齐鲁制药齐倍安®一线治疗宫颈癌III期临床研究达到主要研究终点 qilu-pharma.com ↗
近日，齐鲁制药艾帕洛利托沃瑞利单抗（齐倍安®，QL1706）联合化疗±贝伐珠单抗用于一线治疗持续、复发或转移性宫颈癌的III期临床研究（QL1706-301），经独立数据监查委员会（IDMC）评估已达到无进展生存期（PFS）和总生存期（OS）的双阳性。 |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2026-03-02 | Qilu Pharmaceutical Co., Ltd. | 齐鲁制药齐倍安®一线治疗宫颈癌III期临床研究达到主要研究终点 qilu-pharma.com ↗ |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Iparomlimab and Tuvonralimab | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07854522 ↗ |
| Known as | QL1706 | “Arm A receives neoadjuvant combination of intratumoral OH2 oncolytic HSV2 plus IV QL1706 (Iparomlimab and Tuvonralimab Injection) for 6 q2w cycles before radical surgery,...” NCT07854522 ↗ |
| Modality | Monoclonal antibody | “two engineered monoclonal antibodies” NCT07854522 ↗ |
| Route | Intravenous | “Administered intravenously.” NCT07854522 ↗ |